Qualitative Evaluation to Understand Barriers and Facilitators to Prescribing Angiotensin Receptor-Neprilysin Inhibitors (ARNi) and Sodium-Glucose Cotransporter Inhibitors (SGLT2i) in Patients with Heart Failure with Reduced Ejection Fraction (HFrEF).
質性評估以了解在射血分數降低的心臟衰竭(HFrEF)患者中開立血管緊張素受體-中性酯酶抑制劑(ARNi)和鈉-葡萄糖共轉運蛋白抑制劑(SGLT2i)的障礙與促進因素。
J Am Pharm Assoc (2003) 2024-08-29
Factors affecting prescription of sodium-glucose co-transporter 2 inhibitors in patients with type 2 diabetes mellitus with established cardiovascular disease/ chronic kidney disease in Hong Kong: a qualitative study.
影響香港已患心血管疾病/慢性腎臟病型2糖尿病患者處方鈉葡萄糖共同轉運蛋白2抑製劑的因素:一項質性研究。
BMC Prim Care 2022-12-20
Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors Use among Heart Failure Patients and the Role of Pharmacists in Early Initiation of Therapy.
心衰患者中鈉葡萄糖共同轉運蛋白-2 (SGLT-2) 抑製劑的使用及藥師在早期治療開始中的角色。
Pharmacy (Basel) 2023-03-28
'We are somehow fixated on this being a diabetes drug': a qualitative study exploring the views of cardiologists and nephrologists about sodium-glucose cotransporter 2 inhibitor initiation.
心臟病專家和腎臟病專家對於鈉葡萄糖共轉運輸蛋白2抑制劑開始治療的看法:一項探索性研究。
Intern Med J 2024-04-22
Identifying Barriers and Facilitators for Increasing Uptake of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors in British Columbia, Canada, using the Consolidated Framework for Implementation Research.
在加拿大卑詩省增加鈉葡萄糖共轉運輸蛋白2 (SGLT2) 抑製劑應用的障礙和促進因素:使用整合實施研究框架。
Can J Kidney Health Dis 2024-01-03
Prescribing patterns of SGLT-2 inhibitors for patients with heart failure: A two-center analysis.
心衰患者 SGLT-2 抑制劑的處方模式:兩家醫療中心的分析。
Am Heart J Plus 2024-03-22
A real-world experience of a prescribing policy for SGLT2-inhibitors in HFrEF in a Malaysian public tertiary cardiac centre.
馬來西亞公立三級心臟中心對於SGLT2抑制劑在HFrEF治療中的處方政策的實際經驗。
Med J Malaysia 2024-04-01
Evaluation of Sodium-Glucose Transport Protein 2 (SGLT2) Inhibitor Prescribing Patterns in Heart Failure Patients at Hospital Discharge.
心力衰竭患者出院時鈉葡萄糖轉運蛋白2 (SGLT2) 抑製劑處方模式評估。
J Pharm Pract 2024-05-28